Tumor biomarkers act as important contextual cues or signals of cancer status.
Resources by Therapeutic Area
Genetic Engineering & Biotechnology News| February 15, 2017
John Yan, PhD, from Takeda Pharmaceutical Company presented an ultrasensitive assay format for detecting PD biomarkers in cell and xenograft tumors at the inaugural Powering Precision Health Summit 2016.
Ralph McDade, PhD from Myriad RBM presented a triphase approach to biomarker pattern discovery for cancer immunotherapy and autoimmune disease at the inaugural Powering Precision Health Summit 2016.
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
Journal of Hepatology | July 2016
Metastatic cholangiocarcinomas, cancers that originate from the liver bile ducts, have very limited treatment options and a fatal prognosis. We describe a novel therapeutic approach in such a patient using a personalized multi-peptide vaccine. This vaccine, developed based on the characterization of…
September 8-9, 2016
Brussels, Belgium September 8-9, 2016 Booth #9 Registration at www.eortc.org